Sanofi Consumer

Which are the latest news on Sanofi Consumer?

Why is Sanofi Consumer Healthcare India Ltd falling/rising?

As of 05-Sep, Sanofi Consumer Healthcare India Ltd's stock is rising to Rs 4,219.35, driven by strong recent performance and increased investor interest. However, it faces long-term challenges, including a significant decline over the past year and high valuation concerns.

As of 05-Sep, Sanofi Consumer Healthcare India Ltd's stock price is rising, currently at Rs 4,219.35, with a change of 5.25 (0.12%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.59% today and has been on a consecutive gain streak for the last three days, accumulating a total return of 2.4% during this period. Additionally, there has been a notable rise in investor participation, with delivery volume increasing by 119.02% compared to the 5-day average, indicating heightened interest in the stock.<BR><BR>Moreover, the company has demonstrated strong financial performance, having declared positive results for the last four consecutive quarters. Specifically, net sales for the last nine months grew by 26.89%, and the profit after tax for the latest quarter reached its highest at Rs 68.80 crore, with an earnings per share of Rs 29.91. The company's high management efficiency is reflected in a return on equity (ROE) of 67.74%, and it is also net-debt free, which adds to its financial stability.<BR><BR>However, it is important to note that despite the recent rise, the stock has faced challenges in the long term, with a decline of 18.86% over the past year and underperformance compared to broader indices like the BSE500. The stock's valuation is considered expensive with a price-to-book value of 25.3, and its growth rates in net sales and operating profit over the last five years have been relatively low at 10.10% and 5.70%, respectively. Thus, while the stock is currently rising, it is also navigating a complex landscape of both positive short-term performance and negative long-term growth indicators.

What does Sanofi Consumer do?

Sanofi Consumer Healthcare India Ltd, established on May 10, 2023, focuses on consumer healthcare products following a demerger from Sanofi India Limited. As of June 2026, it reported net sales of 236 Cr and a net profit of 69 Cr, with a market cap of INR 9,581 Cr.

Overview:<BR>Sanofi Consumer Healthcare India Ltd operates in the Pharmaceuticals & Biotechnology industry as a small-cap company focused on consumer healthcare products.<BR><BR>History:<BR>Incorporated on May 10, 2023, Sanofi Consumer Healthcare India Ltd was established as part of Sanofi's global strategy to create a standalone Consumer Healthcare business, resulting from the demerger of the Consumer Healthcare business from Sanofi India Limited. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 236 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 69 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 9,581 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 36.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 1.77% <BR>Debt Equity: -0.98 <BR>Return on Equity: 69.27% <BR>Price to Book: 25.37 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Sanofi Consumer?

Sanofi Consumer's peers include Akums Drugs, Viyash Scientifi, Blue Jet Health, P & G Health Ltd, Strides Pharma, Aarti Pharma, Sanofi India, and Senores Pharma. Akums Drugs leads in 1-year return at 70.88%, while Sanofi India has the lowest at -39.16%, with Sanofi Consumer at -20.12%.

Peers: The peers of Sanofi Consumer are Akums Drugs, Viyash Scientifi, Blue Jet Health, P & G Health Ltd, Strides Pharma, Aarti Pharma, Sanofi India, and Senores Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi Consumer, P & G Health Ltd, and Sanofi India, while Average management risk is found at Akums Drugs, Strides Pharma, Aarti Pharma, and Senores Pharma, and Below Average management risk is noted at Viyash Scientifi. Growth is rated as Good for Viyash Scientifi and Strides Pharma, while Average growth is seen at Akums Drugs, Aarti Pharma, and Sanofi Consumer, and Below Average growth is noted at Blue Jet Health, P & G Health Ltd, Sanofi India, and the rest. Excellent capital structure is present in Akums Drugs, Blue Jet Health, Aarti Pharma, Sanofi Consumer, P & G Health Ltd, and Sanofi India, while Below Average capital structure is found at Viyash Scientifi and Strides Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Akums Drugs at 70.88%, while the peer with the lowest is Sanofi India at -39.16%, with Sanofi Consumer's own 1-year return at -20.12% being significantly lower than Akums Drugs and higher than Sanofi India. Additionally, Sanofi India has a negative six-month return.

How big is Sanofi Consumer?

As of 31st August, Sanofi Consumer Healthcare India Ltd has a market capitalization of 9,581.00 Cr and reported net sales of 949.80 Cr and net profit of 266.00 Cr over the latest four quarters.

As of 31st August, <BR><BR>Market Cap: Sanofi Consumer Healthcare India Ltd has a market capitalization of 9,581.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 949.80 Cr, while the sum of Net Profit for the same period is 266.00 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is December 2025. Shareholder's Funds are valued at 384.00 Cr, and Total Assets amount to 538.50 Cr.

Should I buy, sell or hold Sanofi Consumer Healthcare India Ltd?

Are Sanofi Consumer Healthcare India Ltd latest results good or bad?

Sanofi Consumer Healthcare India Ltd's latest Q1 FY27 results show a net profit increase of 13.35% year-on-year and revenue growth of 6.70%. However, a decline in operating margin to 37.89% raises concerns about profitability amid rising costs.

Sanofi Consumer Healthcare India Ltd's latest results for Q1 FY27 show a mixed performance. On the positive side, the company reported a net profit of ₹68.80 crores, which is a 13.35% increase year-on-year and a 1.47% increase quarter-on-quarter. Revenue also grew by 6.70% year-on-year, reaching ₹235.70 crores, with a sequential growth of 2.84%.<BR><BR>However, there are concerns regarding the operating margin, which declined by 85 basis points to 37.89% compared to the previous quarter. This margin compression indicates challenges in maintaining profitability amidst rising costs and competitive pressures. <BR><BR>Overall, while the company has demonstrated strong profitability and growth in net profit and revenue, the decline in operating margin suggests that it is facing some headwinds. Investors should monitor these trends closely, especially the impact on margins moving forward.

When is the next results date for Sanofi Consumer Healthcare India Ltd?

The next results date for Sanofi Consumer Healthcare India Ltd is 28 July 2026.

The next results date for Sanofi Consumer Healthcare India Ltd is scheduled for 28 July 2026.

Is Sanofi Consumer technically bullish or bearish?

As of December 2, 2025, Sanofi Consumer's technical trend has shifted to a bearish stance, driven by bearish MACD, Bollinger Bands, and moving averages, despite some divergence in longer-term perspectives indicated by Dow Theory.

As of 2 December 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on the weekly, and the OBV shows a mildly bearish trend. The Dow Theory indicates a mildly bearish stance on the weekly but is mildly bullish on the monthly, suggesting some divergence in longer-term perspectives. Overall, the bearish indicators dominate the current technical outlook for Sanofi Consumer.

How has been the historical performance of Sanofi Consumer?

Sanofi Consumer reported net sales of 724.50 crore and a profit after tax of 181.00 crore for the year ending December 2024, reflecting strong growth. Shareholder's funds increased to 273.00 crore, and cash and bank balances rose significantly to 326.90 crore.

Answer:<BR>The historical performance of Sanofi Consumer for the year ending December 2024 shows significant growth in various financial metrics compared to the previous year.<BR><BR>Breakdown:<BR>In December 2024, Sanofi Consumer reported net sales of 724.50 crore, with total operating income also at 724.50 crore. The total expenditure, excluding depreciation, was 453.90 crore, leading to an operating profit (PBDIT) of 283.60 crore. After accounting for interest and exceptional items, the profit before tax stood at 246.80 crore, resulting in a profit after tax of 181.00 crore. The earnings per share (EPS) was reported at 78.7, with a PAT margin of 24.98%. On the balance sheet, shareholder's funds increased to 273.00 crore from 207.60 crore in the previous year, while total liabilities rose to 425.10 crore from 343.50 crore. The total assets also increased to 425.10 crore, with cash and bank balances significantly rising to 326.90 crore from just 1.60 crore in December 2023. The cash flow from operating activities was 439.00 crore, contributing to a net cash inflow of 325.00 crore for the year.

Is Sanofi Consumer overvalued or undervalued?

As of April 19, 2025, Sanofi Consumer is considered very expensive and overvalued with a PE ratio of 57.64, significantly higher than its peers, and has underperformed the Sensex with a recent return of -6.91%.

As of 19 April 2025, the valuation grade for Sanofi Consumer has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a price-to-earnings (PE) ratio of 57.64, a price-to-book value of 42.77, and an EV to EBITDA ratio of 41.78. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Sanofi Consumer's PE ratio is notably higher than Sun Pharmaceutical Industries Ltd. at 35.25 and Cipla Ltd. at 22.99, both of which are considered attractive. Furthermore, the PEG ratio for Sanofi is 0.00, indicating no growth expectations, which contrasts sharply with the more reasonable valuations of its competitors. Recent stock performance shows that Sanofi has underperformed the Sensex over the past week, with a return of -6.91% compared to the Sensex's 1.35%. This reinforces the notion that the stock may be overvalued in the current market context.

Who are the top shareholders of the Sanofi Consumer?

The top shareholders of Sanofi Consumer include Opella Healthcare Participations B.V. with 60.4%, Life Insurance Corporation of India at 5.66%, and individual investors with 6.58%. Additionally, 18 mutual fund schemes hold 15.09%, while 102 foreign institutional investors have a total of 4.53%.

The top shareholders of Sanofi Consumer include Opella Healthcare Participations B.V., which holds the largest stake at 60.4%. Other significant shareholders are the Life Insurance Corporation of India, with a holding of 5.66%, and individual investors collectively owning 6.58%. Additionally, the company has 18 mutual fund schemes holding a combined 15.09% and 102 foreign institutional investors (FIIs) with a total holding of 4.53%. There are no pledged promoter holdings reported.

Has Sanofi Consumer declared dividend?

Yes, Sanofi Consumer Healthcare India Ltd has declared a 550% dividend, amounting to ₹55 per share, with an ex-date of April 17, 2025. However, total returns over the past year and longer periods have been stagnant, showing no price or dividend growth.

Sanofi Consumer Healthcare India Ltd has declared a 550% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 550%<BR>- Amount per share: 55<BR>- Ex-date: 17 Apr 25<BR><BR>Dividend Yield: 1.08%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.2%, the dividend return was 1.14%, resulting in a total return of 6.34%.<BR><BR>In the last 1 year, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the last 2 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 3 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the last 4 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 5 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Sanofi Consumer has declared a significant dividend, the total returns over longer periods indicate a lack of growth in price and dividends, suggesting a mixed performance in terms of shareholder returns.